Efficacité et tolérance de l’association du nivolumab (NIVO) et de l’ipilimumab (IPI) chez des patients atteints d’un mélanome et présentant des métastases cérébrales symptomatiques
Sign Up to like & getrecommendations! Published in 2019 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2019.09.561
Abstract: Introduction Nous avions precedemment rapporte l’efficacite et la tolerance de NIVO + IPI chez des patients (pts) atteints d’un melanome et presentant des metastases cerebrales (MBM) non traitees et asymptomatiques, de l’etude CheckMate 204. Nous presentons ici… read more here.
Keywords: ipi chez; ipi; chez des; nivo ipi ... See more keywords
Facteurs pronostiques et prédictifs associés au traitement par nivolumab et ipilimumab chez les patients présentant un mélanome métastatique
Sign Up to like & getrecommendations! Published in 2020 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2020.09.083
Abstract: Introduction L’association nivolumab et ipilimumab (NIVO + IPI) a considerablement ameliore le pronostic des patients avec melanome metastatique, en particulier en cas de metastases cerebrales. Neanmoins, elle est responsable d’effets indesirables severes dans environ 55 % des cas.… read more here.
Keywords: chez les; les patients; nivo ipi; metastases cerebrales ... See more keywords
ICI for resected stage IV melanoma
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-020-0397-8
Abstract: Immunecheckpoint inhibition (ICI) is an approved treatment approach for both unresectable and completely resected advancedstage melanoma; however, patients with completely resected stage IV disease have been underrepresented in clinical trials to date. In particular, the… read more here.
Keywords: melanoma; ici; disease; nivo ipi ... See more keywords
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1830781
Abstract: Abstract Aims The objective of this study was to evaluate the cost-effectiveness of nivolumab in combination with ipilimumab (nivo + ipi) compared to current therapeutic alternatives in first-line treatment of patients with advanced melanoma from the Japanese… read more here.
Keywords: first line; treatment; japan; nivo ipi ... See more keywords
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-001079
Abstract: Purpose To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell… read more here.
Keywords: ipi sun; renal cell; nivo ipi; ipi ... See more keywords
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005445
Abstract: Background Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients with intermediate/poor-risk sRCC… read more here.
Keywords: nivo ipi; cell; cell carcinoma; renal cell ... See more keywords
Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct077
Abstract: Background: Nivo + ipi showed promising clinical activity and tolerability as 1L tx for advanced NSCLC in a phase 1 study. Tumor mutation burden (TMB) has emerged as an important biomarker for benefit of immune… read more here.
Keywords: initial results; ipi; nivo ipi; lung cancer ... See more keywords
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.4012
Abstract: 4012 Background: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% and median overall survival (mOS) of… read more here.
Keywords: ipi; treated pts; nivo ipi; checkmate 040 ... See more keywords
Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9533
Abstract: 9533 Background: We previously reported a 3-year overall survival (OS) rate of 63% with NIVO+IPI concurrent therapy in the initial phase I dose-escalation study for the combination, conducted in patients (pts) with advanced melanoma. Here,… read more here.
Keywords: nivo ipi; year rates; advanced melanoma; study ... See more keywords
Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.39.28_suppl.305
Abstract: 305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), and… read more here.
Keywords: real world; cell; treatment; nivo ipi ... See more keywords
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9000
Abstract: 9000 Background: In the randomized phase 3 CheckMate 9LA trial (NCT03215706), first-line NIVO + IPI combined with 2 cycles of chemo significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) vs… read more here.
Keywords: ipi chemo; nivo ipi; histology; chemo ... See more keywords